33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) is an inherited disease that accounts for 1–3% of all colorectal malignancies (Lynch and Smyrk, 1996; Peel et al, 2000). On a clinical ground, HNPCC is characterised by increased susceptibility to colorectal and several other neoplasms (especially endometrium, ovary, small bowel and urothelium), early age of cancer onset (frequently under 50 years), a proclivity towards tumours in the right colon (from the cecum to the splenic flexure) and frequent multiple primary tumours in the same patient (Lynch and Smyrk, 1996). Molecular investigations have shown that most HNPCC families are associated with constitutional mutations in a class of genes (called hMSH2, hMLH1, hMSH6, hPMS2 and probably others) which are components of a DNA mismatch repair pathway (Wheeler et al, 2000; Calvert and Frucht, 2002). As a consequence of their inactivation, cells show a generalised genomic instability, which is particularly evident at microsatellite loci (microsatellite instability, MSI) (Aaltonen et al, 1993; Ionov et al, 1993; Thibodeau et al, 1993). Since mutations in any of the DNA mismatch repair genes confer a lifetime risk of cancer of 80–85% (Lynch and Smyrk, 1998a,1998b), regular endoscopic controls in individuals at risk (gene carriers) and removal of all premalignant lesions reduce the colorectal cancer rate in HNPCC families (Jarvinen et al, 1995). There are objective reasons, therefore, for recommending a close endoscopic surveillance to first-degree relatives of the affected individuals, especially in those subjects in whom this increased susceptibility has been further confirmed by genetic testing. Despite the potential benefit, genetic testing and the possible identification of gene carriers may represent a source of stress and anxiety in a given family. This is due to the psychological condition of being genetically ‘different’ from the rest of the population, to loss of privacy and possible discrimination in many social activities (Garber et al, 1997). Indeed, in a recent investigation, Lerman et al (1999) showed that, in four large HNPCC kindreds, more than 50% of the high-risk family members refused further contacts with the investigators or declined genetic counselling. The low rate of acceptance of genetic testing – which was rather unexpected – should raise some concerns on the expected widespread diffusion of this new form of preventive medicine. Since the availability of genetic testing for hMSH2, hMLH1 and hMSH6 gene mutations, we could identify 32 HNPCC families with germline alterations in one of these genes. In the present investigation, we analysed our study group with three specific objectives: first, to evaluate how many high-risk individuals in each family underwent genetic testing for the search of constitutional mutations; second, to ascertain whether mutation-positive unaffected individuals made a proper use of the test (ie, accepted endoscopic surveillance) and, third, to investigate the main findings of endoscopic surveillance in gene carriers. MATERIAL AND METHODS Selection of families Hereditary nonpolyposis colorectal cancer families were assessed in three different centers: the University of Modena (Northern Italy, Region Emilia-Romagna), the Catholic University Medical School in Rome (Central Italy, Region Lazio) and the Aviano Cancer Center (Northern Italy, Region Friuli-Venezia Giulia). In Modena, the families were identified through a multistep approach based on a colorectal cancer registry instituted in 1984 (Ponz de Leon et al, 1987; Ponz de Leon et al, 1999). All tumours of the large bowel diagnosed in the population (265 227 residents at the 1991 census) were registered. The neoplasms were classified according to the International classification of Diseases for Oncology, 9th revision (ICD-O, 1983). Definitions such as ‘carcinoma in situ’, ‘neoplastic foci’ or ‘severe dysplasia’ were not considered as cancer unless there was a clear infiltration of the neoplastic tissue through the muscularis mucosae. Nuclear pedigrees could be obtained in 94% of the registered patients (2462 in the 15-year period 1984–1998). The pedigrees were classified and subdivided according to the presence of clinical criteria indicative of an increased susceptibility to hereditary colorectal cancer (Lynch and Smyrk, 1996). Families showing two or more of these clinical criteria (ie, early age of cancer onset, aggregation of tumours in a sibship, ‘verticality’, proximal location in the large bowel, multiple primaries) were contacted and the pedigrees extended to second- and third-degree relatives. As far as possible, the diagnosis of cancer among family members was verified by histological records, clinical charts or death certificates. In the two other Centres involved in the study (Rome and Aviano), the procedure leading to the identification of HNPCC families was similar to that followed in Modena (ie, definition of nuclear pedigrees, extension of suspected family trees and verification of cancer); the areas, however, were not covered by cancer registries, and individual patients or families with suspicion of HNPCC were referred to the investigators from surgical or endoscopic units operating in those districts. Of the 32 families with constitutional mutations, 25 met the Amsterdam criteria II (Vasen et al, 1999) and seven maintained a strong clinical suspicion of HNPCC, because of familial aggregation and early-onset colorectal cancer. When a kindred showed clinical suspicion of HNPCC, the family doctor was usually contacted for obtaining further information. Subsequently, the proband or other family members were invited by telephone for an education session in one of the centres involved in the study. Families were approached by Internists in Modena, Medical Geneticists in Rome and Gastroenterologists in Aviano. During the session, two members of the staff gathered all relevant information concerning family members (especially cancer development), traced an accurate and extended genealogical tree and required clinical charts or other certifications in order to verify the cancer status. The investigators discussed the general principle of cancer inheritance, advantages and limitations of genetic testing, options of endoscopic surveillance and the possible impact of environmental factors (diet, lifestyle) on cancer-risk reduction. Booklets containing all this information, and further suggestions on diet and style of life, were given to family members at risk. When a kindred was consistent for HNPCC, the successive step was the analysis of microsatellite instability in tumour samples. In the presence of a family history suggestive of Lynch syndrome and of a MSI+ tumour, genetic testing was offered to affected probands from high-risk families, without any charge for the patient and after informed consent. Once a mutation was detected, the family was recontacted and genetic testing was offered to other family members at risk. In most cases, this occurred within 1 year from cancer diagnosis in the proband. Moreover, family doctors, other physicians and collaborative relatives were involved in the attempt to collect further relevant information, particularly with regard to the most distant branches of the family or to individuals living in other regions. Mutation carriers were informed about the need of early colonoscopic surveillance (starting at age 20–25 years), possible benefits and limits of additional screening procedures (endometrial ultrasounds and aspiration biopsy; upper digestive tract endoscopy) and other options aimed at reducing cancer risk (prophylactic interventions, changes in diet and life-style). Noncarriers were reassured, though we made it clear that colorectal cancer is an extremely common disease and that there is large consensus to screen the general population – through fecal occult blood test and lower endoscopy – around the age of 50 years. Microsatellite instability At least one colorectal lesion in each of the 32 families was assessed for MSI, and this was detected in all cases. DNA was extracted from neoplastic and paired normal mucosa, and instability was evaluated with five markers (mono and dinucleotides), as already described (Pedroni et al, 1999). Neoplasms showing instability in two or more loci were scored as unstable (MSI+). PCR products from colorectal tumours and the corresponding normal mucosa of the same patient were loaded in adjacent lanes on a standard 6% denaturating polyacrylamide gel, and visualised by auto-radiography. MSH2, MLH1 and MSH6 protein expression Details of the procedure have already been given (Pedroni et al, 1999). Briefly, formalin-fixed and paraffin-embedded tumour samples from the affected subjects in each family were sectioned at 6 μm, deparaffined and rehydrated. After antigen retrieval, monoclonal antibodies to full-length hMSH2, hMLH1 and hMSH6 proteins (G168-15, G129-1129, Pharmingen and Clone 44 Transduction Labs, USA) were used at 1 : 40 to 1 : 2000 dilution. Tissue samples were stained using diaminobenzidine as chromogen, according to the Nexes Automatic Staining System (Ventana, Strasburg, France). Lesions were considered positive for protein inactivation when a complete absence of nuclear staining was evident in tumour cells against evident nuclear staining of adjacent normal epithelial and stromal cells. Mismatch repair genes mutation analysis As previously reported (Viel et al, 1997), constitutional mutations in the three main DNA mismatch repair genes (hMSH2, hMLH1 and hMSH6) were studied either by single-strand conformation polymorphism (SSCP) or by direct sequencing of the whole genomic region and flanking intron borders using the Big Dye Sequencing Kit (Applera, Foster City, CA, USA) and an applied Biosystem Authomated Sequencer (Applera) on DNA isolated from blood white cells. All families which tested negative by SSCP were subsequently analysed by direct sequencing. Statistical analysis Differences in the occurrence of polyps at endoscopy between gene carriers and noncarriers were evaluated with Z tests for independent proportions, when considering the number of patients with or without polyps. When taking into account the number of lesions, their frequency was applied to the appropriate persons/years at risk in the two groups (mutation + and mutation −), and summary χ 2 tests were used – with the Statistical Package for Social Sciences (SPSS) software – to calculate its statistical significance. RESULTS Figure 1 Figure 1 Clinical and molecular strategies developed for the selection and identification of HNPCC. As far as the experience in Modena is concerned (where a specialised colorectal cancer Registry was instituted in 1984), the number corresponding to each category, for the period 1984–1998, are the following. Registered patients: 2462. Sporadic+familial cases: 2207. HNPCC+suspected HNPCC+early-onset cases: 255. MSI+: 53. Lack of protein expression: 21 (immunohistochemistry). Families which underwent genetic testing: 15. Families with constitutional mutations: 12. shows the strategy that has been followed for the identification of kindreds with inherited colorectal tumours attributable to germline mutations of the main DNA mismatch repair genes. In registered or referred patients, accurate genealogical trees were traced, and, on this basis, a high-risk group for genetic cancer was defined, including HNPCC (according to the Amsterdam Criteria), suspected HNPCC (Park et al, 2002) and early-onset (before the age of 50 years) colorectal cancer, representing some 10–15% of all investigated patients with malignancies of the large bowel. As a successive step, microsatellite instability was assessed in this high-risk group; in MSI+ cases, the expression of the protein encoded by the three main mismatch repair genes was evaluated by immunohistochemistry in tumour samples. Lack of protein expression was followed by search of constitutional mutations of the corresponding gene, in the proband and in other family members. With this algorithm, 32 families with germline mutations were identified, between 1994 and 2001. Details of individual families characterised by constitutional mutations (Viel et al, 1997,1998; Lucci-Cordisco et al, 2001) are shown in Table 1 Table 1 Individual families characterised by germline mutations in DNA mismatch repair genes during the period 1994–2001   Family Gene Mutation Investigated individuals Mutation positive affecteda/nonaffectedb Mutation negativec Total individuals at riskd Individuals at risk nonevaluatede(%)f 1. MO-1 hMLH1 2270ins 10 4/2 4 8 2 2. MO-2 hMSH2 1243–1246del 4 1/1 2 11 8 3. MO-4 hMLH1 IVS17(+5)G>C 4 2/0 2 14 12 4. MO-10 hMSH2 IVS6(+3)A>T 14 5/0 9 32 23 5. MO-20 hMLH1 2270ins 2 2/0 0 12 12 6. MO-27 hMLH1 2270ins 7 4/0 3 12 9 7. MO-29 hMLH1 2270ins 11 2/3 6 21 12 8. MO-32 hMSH2 W345X 1 1/0 0 4 4 9. MO-39 hMSH2 2647del 17 5/1 11 31 19 10. MO-35 hMSH2 IVS5(+3)A>T 6 3/2 1 8 5 11. MO-41 hMSH6 2984del 4 1/1 2 5 2 12. MO-44 hMLH1 1542ins 2 2/0 0 5 5 13. RM-1 hMLH1 Del 2.5 kb 4 3/0 1 5 4 14. RM-2 hMLH1 597–598del 7 2/2 3 11 6 15. RM-3 hMSH2 1497del 3 2/1 0 8 7 16. RM-4 hMSH2 1705insGA 4 1/0 3 3 0 17. RM-5 hMLH1 1520insT 13 4/2 7 15 6 18. RM-6 hMLH1 1846–1848del 4 2/0 2 7 5 19. AV-24 hMLH1 IVS7(-2)A>G 5 2/1 2 11 8 20. AV-2 hMLH1 Q301X 10 2/1 7 8 1 21. AV-14 hMLH1 1783–1784del 3 1/0 2 2 0 22. AV-20 hMLH1 Del 2.5kb 1 1/0 0 2 2 23. AV-4 hMSH6 1960insGTGA 1 1/0 0 0 0 24. AV-17 hMSH2 Q824X 6 2/1 3 6 2 25. AV-39 hMSH2 S473X 4 1/1 2 4 1 26. AV-28 hMSH2 C778X 2 1/0 1 5 4 27. AV-52 hMSH2 399del 7 4/2 1 8 5 28. AV-56 hMSH2 840insT 1 1/0 0 8 8 29. AV-60 hMSH2 IVS6(-2) A>C 1 1/0 0 2 2 30. AV-68 hMSH2 R406X 2 1/1 0 15 14 31. AV-91 hMSH2 Q824X 3 1/1 1 4 2 32. AV-87 hMSH2 C697R 1 1/0 0 5 4   Total hMLH1 (14)   164 66/23 75 292 194 (66.4%)     hMSH2 (16)                 hMSH6 (2)             a Patients affected by colorectal (or other malignancy of the HNPCC system) at diagnosis. b First-degree relatives in whom genetic testing showed constitutional mutations. c First-degree relatives in whom genetic testing showed wild-type gene. d In each family, first-degree relatives of affected individuals over the age of 20 years. e In each family, individuals at risk who did not undergo genetic testing. f Percent of total individuals at risk. . A total of 164 individuals could be assessed by genetic testing (on average, five per family); 89 were gene carriers (66 affected and 23 nonaffected) and 75 tested negative (ratio: 1.18, not far from the 1 : 1 expected for autosomal dominant transmission). Among the 23 unaffected gene carriers, 19 (82.6%) underwent pancolonoscopy within 1–2 years from the test results, while four declined. Reasons for denial were young age (19 and 21 years, two subjects), ‘lack of time’ associated with some fear of invasive procedures in the other two. On a total of 292 first-degree relatives of affected individuals over the age of 20 years, 194 (66.4%) did not undergo genetic testing. The number of subjects who could be assessed varied from family to family, but was apparently unrelated to the dimension of the kindred, site of origin and level of education. The main reasons for not executing genetic tests were: (a) difficulty (or impossibility) to reach and contact family members (65%); (b) lack of collaboration (15%); (c) lack of interest in preventive (or ‘predictive’) medicine or ‘fatalistic’ attitude towards cancer occurrence or unspecified reasons (20%). Most mutations were found in hMSH2 (16; 50%) or hMLH1 (14; 44%) genes; families MO-1, MO-2, MO-26 and MO-27 showed the same germline alteration. The four families segregating this unusual mutation were resident in the same area, a finding which could be explained by a founder effect (manuscript submitted for publication). Table 2 Table 2 Endoscopic surveillance and tumour occurrence in gene carriers and in controls (mutation negative) Groups n Mean age at first endoscopy (years)+s.d. All polyps detected Adenomas No. patients with polyps Other neoplasms developed during follow-up Mutation+a 19 33.1±8.7 17* 11** 7 (36.8%)*** 3 (endometrium, thyroid, colon) Mutation −b 19 38.5±13 3 3 2 (10.5%) 2 (endometrium, breast) a Gene carriers, that is, first-degree relatives of affected individuals in whom genetic testing showed the presence of a constitutional mutation. b Mutation negative, that is, first-degree relatives of affected individuals in whom genetic testing showed wild-type gene. * P<0.001 by summary χ 2 test. ** P=0.003 by summary χ 2 test. *** Z=3.22, P<0.01. shows the main endoscopic findings of gene carriers who accepted to be screened. As a control group, we selected those noncarriers who underwent colonoscopy before knowing the test results or despite their low risk status, owing to anxiety or need of more reassuring procedures. Although gene carriers were younger than controls (average difference: 5 years), the number of lesions (adenomatous or hyperplastic polyps, or carcinomas) detected at endoscopy was significantly (P<0.001) higher in the carriers. Moreover, colorectal lesions were found in seven high-risk subjects (of 19, 36.8%), but in two controls only (of 19, 10.5%) (P<0.01). The length of follow-up was similar in the two groups (4.9±2.6 vs 6.5±2.4 years in controls), while the number of colonoscopic investigations/patient was 1.50 in the high-risk group and 1.45 in noncarriers. DISCUSSION The results of the present investigation show that a large fraction of high-risk individuals in mutation-positive HNPCC families does not undergo genetic tests, despite their availability. Among examined subjects, the large majority of gene carriers follows the recommendations, and is willing to undergo colonoscopic surveillance. Despite the relatively young age of gene carriers, the results of endoscopy show an increased risk for polyps and adenomas. Our findings are similar to those obtained by Lerman and collaborators with American HNPCC families, in whom 43% only of high-risk subjects participated in their counselling and testing program (Lerman et al, 1999). Among the reasons for this relative lack of success, the authors gave emphasis to low education and frequent presence of depression symptoms in their study group. It should be noted that the American experience is based on the analysis of four large kindreds, and that most individuals at risk could be contacted directly, by letter or telephone. In our study, 32 families scattered in various Italian regions were analysed, and this prevented us from evaluating the role of strictly personal factors, such as the level of education and presence of depression. Once the accurate examination of a family tree raises the suspicion of HNPCC, molecular analysis can be undertaken to definitely establish the diagnosis. As recently pointed out by Terdiman (2001), this is not a truly essential step, since the fundamental factor for saving lives is to identify high-risk individuals based on clinical grounds, and to ensure that they receive appropriate surveillance, whether detected to have a mutation or untested. Indeed, the fraction of HNPCC in which mismatch repair gene mutations can be identified ranges between 30 and 60% of all families (the fraction is even lower in the so-called suspected HNPCC), and this means that in approximately half of these kindreds endoscopic surveillance should be initiated simply on a clinical basis (Aaltonen et al, 1998; Lynch and Smyrk, 1998a,1998b; Wijnen et al, 1998). However, when a constitutional mutation is found in a HNPCC family, we feel ‘a step forward’, in the sense that high-risk individuals can be precisely identified, and endoscopic surveillance can be limited to gene carriers, thus avoiding unnecessary early investigations in many subjects. It is rather disappointing, therefore, that both the study of Lerman et al (1999) and the present investigation clearly show that there are still barriers to the widespread diffusion of genetic testing. In our experience, the main limiting factor was the difficulty in reaching and contacting directly all family members at risk. As indicated by current guidelines, we preferred to adopt a ‘soft’ attitude, avoiding direct telephone calls to distant relatives of the proband and encouraging relatives to talk each other about the risk of cancer running in the family, and the possibilities of prevention and early diagnosis. Moreover, whenever possible, family doctors were contacted and informed about the family history. However, their involvement – though occasionally helpful – had a limited impact in alerting high-risk individuals. It is of interest that the relatively more active attitude of Lerman et al (1999) and our less interfering approach gave basically the same results. Lack of collaboration and poor interest in the novel approaches offered by molecular medicine were relevant factors limiting the diffusion of genetic testing also within our HNPCC families. We noticed that a fatalistic attitude to cancer occurrence is still frequent and, surprisingly, often independent by the level of education. To the arguments that cancer was so common among close relatives and that there are tests available for knowing the level of risk, answers such as ‘I do not want to know my risk level, I prefer not to be upset’ or ‘Cancer is so frequent, and there is no way to escape it’, were not uncommon. The fact that the large majority of mutation carriers underwent endoscopic surveillance is more reassuring. We are not surprised that some individuals hesitated before accepting endoscopy in their 20s or 30s, simply on the basis of a test result. Colonoscopy, even with proper sedation, remains an embarrassing and often painful procedure, which requires a long and disturbing preparation. However, our data suggest that surveillance is acceptable to most, if not all, mutation carriers. Noncarriers can be reassured about their low risk of colorectal cancer and the fact that early colonoscopy is not necessary. Nevertheless, some 30% of them underwent endoscopic controls before the age of 40 years, usually because of anxiety. Since the lifetime risk of colorectal cancer in the Western population is in the order of 5–6% (Black et al, 1997), and the same holds true for noncarriers within HNPCC families, we believe that the attention of mutation-negative individuals to the possible event of common malignancies should not be completely discouraged. Indeed, endoscopy in noncarriers showed adenomatous polyps in two of them (10.5%), at an average age of 38 years (Table 2). Finally, the finding of early-onset polyps in one out of three of gene carriers and the frequency of adenomatous lesions are not surprising, and confirm previous investigations (Jarvinen et al, 2000; de Vos tot Nederveen Cappel et al, 2002). These results further emphasise the importance of a strict endoscopic surveillance in all individuals at risk, in HNPCC families, starting at age 20–25 years (Lindblom and Nordenskjold, 1999, Giardiello et al, 2001). Moreover, they reinforce the concept that cancer in these families develops through the adenoma–carcinoma sequence, as in sporadic colorectal cancer. In conclusion, the main message of the present investigation is that, at present, there are still relevant barriers to genetic testing in HNPCC families and, consequently, we are not able to provide adequate protection against cancer development even in kindreds with identified constitutional mutations. Better education of patients, institution of specialised units entirely devoted to inherited tumours and further collaboration with mass media might help molecular medicine to reach the objective of saving lives (Julian-Reynier et al, 1996; Lee et al, 2002).

          Related collections

          Most cited references 30

          • Record: found
          • Abstract: found
          • Article: not found

          Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.

          Spontaneous errors in DNA replication have been suggested to play a significant role in neoplastic transformation and to explain the chromosomal alterations seen in cancer cells. A defective replication factor could increase the mutation rate in clonal variants arising during tumour progression, but despite intensive efforts, increases in tumour cell mutation rates have not been unambiguously shown. Here we use an unbiased genomic fingerprinting technique to show that 12 per cent of colorectal carcinomas carry somatic deletions in poly(dA.dT) sequences and other simple repeats. We estimate that cells from these tumours can carry more than 100,000 such mutations. Only tumours with affected poly(dA.dT) sequences carry mutations in the other simple repeats examined, and such mutations can be found in all neoplastic regions of multiple tumours from the same patient, including adenomas. Tumours with these mutations show distinctive genotypic and phenotypic features. We conclude that these mutations reflect a previously undescribed form of carcinogenesis in the colon (predisposition to which may be inherited) mediated by a mutation in a DNA replication factor resulting in reduced fidelity for replication or repair (a 'mutator mutation').
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.

              Identification of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome enables prevention of colorectal cancer (CRC) by means of colonoscopy and polypectomies. We evaluated the efficacy of screening in a controlled trial over 15 years. Incidence of CRC and survival were compared in 2 cohorts of at-risk members of 22 families with HNPCC. Colonic screening at 3-year intervals was arranged for 133 subjects; 119 control subjects had no screening. Genetic testing was offered to subjects in whose families the causative mutation was known. CRC developed in 8 screened subjects (6%) compared with 19 control subjects (16 %; P = 0.014). The CRC rate was reduced by 62%. In mutation-positive subjects alone, the CRC rates were 18% in screened subjects and 41% in controls (P = 0.02). The decrease resulted from the removal of adenomas in 13 mutation-positive individuals (30%) and in 6 subjects with unknown mutation status (40%). All CRCs in the study group were local, causing no deaths, compared with 9 deaths caused by CRC in the controls. The overall death rates were 10 vs. 26 subjects in the study and control groups (P = 0.003), 4 vs. 12 in mutation-positive subjects (P = 0.05). Colonoscopic screening at 3-year intervals more than halves the risk of CRC, prevents CRC deaths, and decreases overall mortality by about 65% in HNPCC families.
                Bookmark

                Author and article information

                Journal
                Br J Cancer
                British Journal of Cancer
                Nature Publishing Group
                0007-0920
                1532-1827
                17 February 2004
                23 February 2004
                : 90
                : 4
                : 882-887
                Affiliations
                [1 ] 1Dipartimento di Medicine e Specialità Mediche, Medicina I, Università di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, Modena 41100, Italy
                [2 ] 2Divisione di Anatomia Patologica, Ospedale di Carpi, Modena, Italy
                [3 ] 3Dipartimento di Anatomia Patologica, Università di Modena e Reggio Emilia, Italy
                [4 ] 4Unità di Genetica Medica, Dipartimento di Fisiopatologia Clinica, Università di Firenze, Italy
                [5 ] 5Oncologia Sperimentale 1 e Gastroenterologia, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
                [6 ] 6Istituto di Genetica Medica, Università Cattolica ‘A.Gemelli’, Roma
                [7 ] 7Divisione di Gastroenterologia, Ospedale di Viterbo, Italy
                Author notes
                [* ]Author for correspondence: deleon@ 123456unimo.it
                Article
                6601529
                10.1038/sj.bjc.6601529
                2410159
                14970868
                Copyright 2004, Cancer Research UK
                Categories
                Genetics and Genomics

                Oncology & Radiotherapy

                cancer, msi, rectum, hnpcc, colon, tumour

                Comments

                Comment on this article